

More information on the trials listed below is available at PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov. A searchable Web site developed by the National Library of Medicine is also available at clinicaltrials.gov.

Phase II

Phase II Randomized Study of Gemcitabine Hydrochloride and Tanespimycin (17-AAG) in Patients With Stage IV Pancreatic Adenocarcinoma
NCT00577889

Phase II Study of an Individualized Drug Treatment Selection Process Based on a Tumor Xenograft Model for Patients With Resectable Pancreatic Adenocarcinoma
NCT00276744

Phase II Study of Neoadjuvant Erlotinib Hydrochloride in Patients With Resectable Intraductal Pancreatic Mucinous Neoplasm
NCT00482625

Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreatic Adenocarcinoma
NCT00536874

Phase II Randomized Study of Erlotinib Hydrochloride and Gemcitabine Hydrochloride With Versus Without Panitumumab in Patients With Previously Untreated, Metastatic Adenocarcinoma of the Pancreas
NCT00550836

Phase II Study of Neoadjuvant Therapy Comprising Gemcitabine, Oxaliplatin, Fluorouracil, Bevacizumab, and Radiotherapy and Adjuvant Therapy Comprising Gemcitabine and Bevacizumab in Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
NCT00602602

Phase II Study of Neoadjuvant and Adjuvant Gemcitabine Hydrochloride and Erlotinib Hydrochloride in Patients With Resectable Adenocarcinoma of the Pancreas Undergoing Pancreatectomy
NCT00733746

Phase III

Randomized Study of Gemcitabine Hydrochloride and Erlotinib Hydrochloride With Versus Without Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 as First-Line Therapy in Patients With Unresectable Metastatic Pancreatic Cancer
NCT00617708

Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
NCT00438256

Phase I

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer
NCT00364364

No Phase Specified

Randomized Study of Neoadjuvant and Adjuvant GVAX Pancreatic Cancer Vaccine With or Without Single-Dose or Metronomic-Dose Cyclophosphamide in Patients Undergoing Chemoradiotherapy for Resectable Stage I or II Adenocarcinoma of the Pancreas
NCT00727441

The following trials are currently being conducted at Moffitt Cancer Center. For additional information about these trials, please visit MOFFITT.org or call Cheryl Maker in the Clinical Research Department at (813) 745-4106 or e-mail cheryl.maker@moffitt.org.

Phase III

Randomized, Double-blinded Study of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo for the First-Line Treatment of Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
MCC 15237

Phase II/III

Randomized Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
MCC 15223

Phase II

Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer
MCC 15587

Phase IIA

Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms
MCC 15450

Phase IB

Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer
MCC 15613

Phase I

Trial of GemCap-T, Capecitabine in Combination With Gemcitabine and Erlotinib in Patients With Advanced Pancreatic Adenocarcinoma
MCC 14624

No Phase Specified

High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
MCC 14882